Back to Journals » Patient Related Outcome Measures » Volume 10

Lubiprostone in the treatment of chronic idiopathic constipation: an update on health-related quality of life and patient-reported outcomes

Authors Hayat M, Zia H, Nusrat S

Received 4 September 2018

Accepted for publication 3 January 2019

Published 12 February 2019 Volume 2019:10 Pages 43—47


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Robert Howland

Maham Hayat,1 Hassaan Zia,2 Salman Nusrat2

1Department of Internal Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; 2Section of Digestive Diseases & Nutrition, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA

Abstract: Chronic idiopathic constipation, if inadequately treated, can be bothersome with a detrimental effect on patients’ quality of life (QOL). This may also result in frequent health care visits, increasing the burden of this ailment’s medical cost. Management strategies, focused on lifestyle changes, include increased exercise, a high-fiber diet, and toilet training. Pharmacologic options include fiber supplementation, laxatives, serotonergic agents, and prosecretory agents such as lubiprostone. In this review, we were able to conclude that lubiprostone, when used for chronic idiopathic constipation, has a significantly beneficial effect on both patients’ symptoms and their QOL. In multiple randomized controlled trials, it has been found to have increased the number of spontaneous bowel movements at different time endpoints. Corresponding improvements were also observed for abdominal bloating, discomfort, stool frequency, and straining symptoms among patients.

Keywords: functional, gastrointestinal disorders, spontaneous bowel movements, secretory agents, abdominal pain, cost-effectiveness

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]